ELEVAI LABS, INC. UNDERWRITING AGREEMENTLock-Up Agreement • November 21st, 2023 • Elevai Labs Inc. • Pharmaceutical preparations • New York
Lock-Up AgreementLock-Up Agreement • November 24th, 2023 • Elevai Labs Inc. • Pharmaceutical preparations
This Lock-Up Agreement (this “Agreement”) is being delivered to Univest Securities, LLC and Webull Financial LLC (the “Representatives”) in connection with the proposed Underwriting Agreement (the “Underwriting Agreement”) between Elevai Labs, Inc., a Delaware corporation (the “Company”), and the Representatives, relating to the proposed public offering (the “Offering”) of common stock, par value $0.0001 per share (“Common Stock”), of the Company. Capitalized terms used in this Agreement and not otherwise defined herein shall have the respective meanings given to them in the Underwriting Agreement.
AMENDED AND RESTATED CONSULTING AGREEMENTConsulting Agreement • September 29th, 2023 • Elevai Labs Inc. • Pharmaceutical preparations • California
AUTHORIZED DISTRIBUTOR AND TRADEMARK LICENSE AGREEMENTAuthorized Distributor and Trademark License Agreement • September 29th, 2023 • Elevai Labs Inc. • Pharmaceutical preparations • Delaware
Elevai Labs Inc. (“Company”) recognizes the time and resources our high-quality distributors (hereinafter, “Distributors”) invest in delivering excellent customer experiences through knowledgeable staff, marketing initiatives and compelling sales presentations and support. To support our Distributors’ efforts, Company wishes to establish policies that allow Distributors to earn the profits necessary to maintain the high level of customer excellence the industry has come to expect from Company’s Distributors.
STOCK TRANSFER AGREEMENTStock Transfer Agreement • September 29th, 2023 • Elevai Labs Inc. • Pharmaceutical preparations • California
This Stock Transfer Agreement (this “Agreement”) dated as of June 4 , 2021 (“Effective Date”) is entered into by and between BWL Investments Ltd. (the “Transferor”) and Reactive Medical Labs Inc., a Delaware corporation (the “Transferee”). Reactive Medical Inc., a company incorporated under the laws of the Province of British Columbia, Canada (the “Company”) has executed this Agreement solely to acknowledge the transfer of the shares of Company effected hereby.
License AgreementLicense Agreement • January 22nd, 2024 • Elevai Labs Inc. • Pharmaceutical preparations • New York
This License Agreement (“Agreement”) is made effective as of the date of last signature below (“Effective Date”), by and between INmune Bio Inc., a corporation formed under the laws of the state of Nevada and having an address at 225 NE Mizner Blvd., STE 640, Boca Raton, FL 33432 U.S.A. (“INmuneBio”), and Elevai Labs, Inc., a Delaware corporation with an address located at 1120 Newport Center Drive, Suite 250, Newport Beach, California 95618 (“Licensee”). Each of INmuneBio and Licensee may be individually referred to herein as a “Party,” and collectively as the “Parties”.
License AgreementLicense Agreement • May 2nd, 2024 • Elevai Labs Inc. • Pharmaceutical preparations • Delaware
This License Agreement (“Agreement”), dated as of April 30, 2024 (the “Effective Date”), is by and between MOA Life Plus Co., Ltd., a corporation duly organized and existing under Korean law, with its head office at A-7F U-Tower, 767, Sinsu-ro, Suji-gu, Yongin-si, Gyeonggi-do, 16827, Korea, hereby represented by Sangjin Han, Chairman (hereinafter referred to as “MOA”), and Elevai Labs Inc., a corporation existing under the laws of Delaware, with its headquarters located at 120 Newport Center Drive, Suite 250, Newport Beach, California 92660, U.S.A., hereby represented by Jordan Plews (hereinafter referred to as “Elevai”) (collectively, the “Parties,” or each, individually, a “Party”).
ADVISORY AGREEMENTAdvisory Agreement • September 29th, 2023 • Elevai Labs Inc. • Pharmaceutical preparations • California
COLLABORATION & LICENSE AGREEMENTLicense Agreement • December 5th, 2023 • Elevai Labs Inc. • Pharmaceutical preparations • New York
This Collaboration and License Agreement (this “License Agreement” or “Agreement”) is made and entered into as of the date of the last signature herein (the “Effective Date”), by and between Yuva Biosciences, Inc., a Delaware corporation with its principal place of business at 1500 First Avenue N, Suite L133, Birmingham, AL 35203 (“Yuva Bio”), and Elevai Labs, Inc., a Delaware corporation with its principal place of business at 1120 Newport Center Drive, Suite 250, Newport Beach, California 95618 (“ELEVAI”). In this Agreement, Yuva Bio and ELEVAI are collectively referred to as the “Parties” and each individually as a “Party”.
CONSULTING AGREEMENTConsulting Agreement • May 9th, 2024 • Elevai Labs Inc. • Pharmaceutical preparations • Delaware
This Consulting Agreement (this “Agreement”), effective as of May 3, 2024 (“Effective Date”), is entered into by and between Elevai Labs Inc., a Delaware corporation (“Company”), and Santorio Biomedical, LLC, a Delaware limited liability company (“Consultant”).
AUTHORIZED DISTRIBUTOR AGREEMENTAuthorized Distributor Agreement • September 29th, 2023 • Elevai Labs Inc. • Pharmaceutical preparations • Delaware
Elevai Labs Inc. (“Company”) recognizes the time and resources our high-quality distributors (hereinafter, “Distributors”) invest in delivering excellent customer experiences through knowledgeable staff, marketing initiatives and compelling sales presentations and support. To support our Distributors’ efforts, Company wishes to establish policies that allow Distributors to earn the profits necessary to maintain the high level of customer excellence the industry has come to expect from Company’s Distributors.
